Related Experiment Video

Updated: Sep 26, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Potential pitfalls in the use of surrogate endpoints in colorectal adenoma chemoprevention

Bernard Levin

    Journal of the National Cancer Institute
    |May 22, 2003
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Experiment Videos

    Last Updated: Sep 26, 2026

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
    06:46

    Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

    Published on: September 27, 2024

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
    08:12

    Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

    Published on: March 14, 2019

    Related Concept Videos

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

    Articles linked to this work by shared authors, journal, and citation graph.

    Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.

    Journal of medicinal chemistry·2026

    Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.

    Nature·2025

    Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity.

    Journal of medicinal chemistry·2025

    Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity.

    bioRxiv : the preprint server for biology·2024

    An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles.

    Gut·2023

    Performance analysis of a machine learning flagging system used to identify a group of individuals at a high risk for colorectal cancer.

    PloS one·2017

    21-Gene recurrence score assay in pN2-3 Early-Stage breast cancer: a national cancer database study.

    Journal of the National Cancer Institute·2026

    Projected impact of population-level multi-cancer early detection screening: a discrete event simulation analysis.

    Journal of the National Cancer Institute·2026

    Late effects after novel therapies for childhood cancer: Anticipating the future landscape of health outcomes for survivors.

    Journal of the National Cancer Institute·2026

    Hysterectomy-corrected incidence of cervical cancer among women with HIV in the United States, 2001-2019.

    Journal of the National Cancer Institute·2026

    Markers of cervical intraepithelial neoplasia grade 2 regression and subsequent risk of CIN3.

    Journal of the National Cancer Institute·2026

    An artificial intelligence algorithm characterizes the deterioration of body composition from systemic therapy for patients with advanced prostate cancer.

    Journal of the National Cancer Institute·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us